This News May Top Anything Else Moderna Says During Its Earnings Report
Moderna's (NASDAQ: MRNA) third-quarter earnings report on Thursday is sure to be chock-full of exciting numbers and news. Investors are expecting another billion-dollar quarter. That's thanks to sales of the company's coronavirus vaccine. And I'll be watching for details -- such as future vaccine orders -- that could determine Moderna's path moving forward.
But no matter what Moderna has to say, it will be difficult to top something the company announced last week. Why? This news brings a potential blockbuster product one major step closer to commercialization. In fact, this candidate's next step should be a regulatory submission. Let's take a closer look at what may be Moderna's next billion-dollar revenue driver.
Image source: Getty Images.
Source Fool.com
